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1. Introduction 
Advances in systemic chemotherapy and radiotherapy have had a profound effect on the 
prognosis of patients affected by many cancer histotypes. Nonetheless, one of the main 
challenges for modern oncology is in improving the tolerability of these treatments. The 
frequency and pathophysiology of the most common side effects induced by cytotoxic 
agents are well known. They may be immediate or delayed in onset and prevalently involve 
bone marrow, gastrointestinal system, liver, and cutaneous annexes. 
Abnormalities in thyroid function and thyroid disease are variably associated with cancer or 
cancer therapy [1]. These disorders encompass a broad variety of pathophysiological 
mechanisms, may be subtle in presentation, sometimes difficult to be identified, and even 
more difficult to relate to a particular chemotherapeutic regimen due to the lack of specific 
wide clinical trials [2]. The alteration of thyroid hormone metabolism, more commonly 
known as “euthyroid sick syndrome”, may occur in patients with advanced cancers. 
Thyroid dysfunction, such as the altered synthesis or clearance of thyroid hormone-binding 
proteins are observed in certain malignancies, or may be caused by treatments that modify 
total but not free concentration of thyroid hormones. However, the clinical influence of this 
abnormalities is marginal, if any. 
Endocrine disorders are among the most commonly reported long-term complications of 
cancer treatment by adult survivors of childhood cancers [3]. In adults, cytotoxic drugs are 
infrequently associated to overt endocrine toxicity. However, excluding gonadotoxic 
consequence [4], only few studies thoroughly evaluated the endocrine dysfunction induced 
by cytotoxic anticancer therapy in this population [2]. Similarly, hormonal therapies, widely 
used as effective treatment of patients affected by endocrine responsive breast cancer and 
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prostate cancer, have shown only marginally influence on thyroid function and thyroid 
toxicities attributed to these drugs are anecdotic. 
In contrast to cytotoxics and hormonal therapies, several novel antineoplastic agents, 
including targeted therapies and immunotherapies, are unexpectedly associated with 
thyroid dysfunction and thyroid disease, despite their high selectivity of action [5]. 
Even diagnostic procedures using iodinated contrast agents can be associated with acute 
effects on the thyroid, including hyperthyroidism (i.e. in patients with thyroid autonomous 
nodules or mild Graves disease), or transient hypothyroidism (i.e. in patients with 
Hashimoto thyroiditis) [6,7]. Radiation therapy can be responsible for hypothyroidism from 
direct damage on the thyroid or secondary to hypopituitarism from brain irradiation. 
Irradiation received during childhood has been associated with thyroid nodules and thyroid 
cancer [8]. 
In this chapter, available data on thyroid abnormalities induced by anticancer drugs only 
are discussed. 
2. Cytotoxic agents 
Cytotoxic chemotherapy seems to alter endocrine functions in a relatively small proportion 
of patients and is infrequently associated with thyroid abnormalities in the absence of 
irradiation. Cytotoxics may sensitize the thyroid gland to the effects of concomitant 
radiation therapy, increasing the risk of radiation-induced primary hypothyroidism [9]. 
In a small published series, some agents such as 5-fluorouracil, glucocorticoids, estrogens, 
tamoxifen, podophyllin and L-asparaginase alter levels of thyroid hormone–binding 
proteins without any clinical consequence [10-15]. L-asparaginase can also be responsible for 
transient hypothalamic or pituitary hypothyroidism [16]. Other agents such as lomustine, 
vincristine, and cisplatin have in vitro effects on thyroid cells, but clinically relevant 
consequences have not been reported [17]. Mitotane is the only active agent against 
advanced adrenocortical cancer (ACC) and is under evaluation in patients who underwent 
radical resection of this rare disease. Mitotane showed a complex interference on the 
endocrine system that may require multiple hormone replacement therapy. In a prospective 
trial [18] on 17 patients who underwent radical resection for ACC, a marked reduction in 
free-T4 (FT4) levels was found, without any significant changes in serum thyroid 
stimulating hormone (TSH) and free-T3 (FT3) concentration. FT4 reduction was inversely 
correlated with mitotane concentrations and dropped in the hypothyroid range in most 
evaluable patients. These findings mimic central hypothyroidism and are consistent with 
data from clinical experiments which showed that mitotane directly reduces both secretory 
activity and cell viability on pituitary TSH-secreting mouse cells [19]. Alternatively, it has 
been suggested that mitotane may affect deiodase activity, thus changing the FT4 to FT3 
ratio. However, despite limited information on free thyroid hormone concentrations during 
mitotane treatment has been reported, for some patients thyroxine replacement may be 
necessary [20]. 
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An increased incidence of primary hypothyroidism has been documented in patients treated 
with multiple drug regimens, with or without radiotherapy [2]. In patients with testicular 
cancer who received combinations of cisplatin, bleomycin, vinblastine, etoposide, and 
dactinomycin, 4 out of 27 individuals (15%) developed primary hypothyroidism. In 
particular, the cumulative doses of cisplatin and vincristine seem to exacerbate these 
symptoms [21]. In another trial evaluating the combination of mechlorethamine, vinblastine, 
procarbazine and prednisolone (MOPP regimen) as treatment of Hodgkin’s disease, 44% of 
patients developed elevated serum TSH concentrations, even though a causative role of 
iodine load during lymphangiograpy cannot be excluded [22]. Children with brain tumors 
(not involving the hypothalamic-pituitary axis) who receive vincristine, carmustine or 
lomustine, and procarbazine in combination and brain irradiation have a 35% incidence of 
hypothyroidism, compared with a 10% incidence in the group with brain irradiation alone 
[23]. Young age and use of chemotherapy have been associated with a higher incidence of 
hypothyroidism in patients receiving radiotherapy for medulloblastoma [24]. Again, the 
highest incidence occurred when the thyroid gland was included in the radiation field. 
Finally, there is no evidence that cytotoxic agents by itself may represent a risk factor for 
developing thyroid tumors, compared to radiotherapy [2]. 
3. Immunoregulatory agents 
3.1. Cytokines 
3.1.1. Interferon- 
Interferon- is a human recombinant cytokine that increases the expression of major 
histocompatibility complex (MHC) class I and tumor-specific antigens on the tumor cell 
surface, stimulating immune-mediated destruction of these cells, as well as possibly exerting 
direct antitumor effects [25]. Interferon- demonstrated variable efficacy in patients affected 
by melanoma, renal cell carcinoma (RCC), AIDS-related Kaposi's sarcoma, follicular 
lymphoma, hairy cell leukemia, and chronic myelogenous leukemia [25]. Reduction in viral 
load is another relevant activity of interferons. In combination with ribavidin, interferon- 
prolongs survival in patients with hepatitis C [26,27]. Flu-like syndrome, malaise, 
neuropsychiatric disorders, hematologic and liver toxicity are the most common dose-
limiting side-effects. 
Thyroid diseases secondary to treatment with Interferon- are common and may become 
clinically evident as destructive thyroiditis, autoimmune hypothyroidism or Graves-like 
hyperthyroidism. Patients receiving the drug for hepatitis appear more prone to present 
thyroid dysfunction than patients with malignant disease [28]. However, the infection from 
the hepatitis C virus itself has been demonstrated to increase the risk of thyroid damage 
[28]. The pegylated form of interferon- is more effective than interferon- in triggering 
antiviral response, but showed a similar rate of thyroid dysfunction [29]. 
Destructive or autoimmune thyroiditis is the most common thyroid abnormality following 
treatment with interferon-. This condition may lead to hypothyroidism after a brief 
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thyrotoxic phase and usually occurs in the first few weeks of interferon treatment and is in 
close temporal relationship with the appearance of thyroid autoantibodies, especially anti-
thyroglobulin (anti-TG) antibodies. Another form of autoimmune thyroid toxicity associated 
to interferon- is characterized by the development of thyroid antibodies without 
hypothyroidism. In the setting of interferon therapy, the risk of hypothyroidism is 2.4%–
10% [30-35], with a risk of thyroid autoimmunity onset (including development of thyroid 
autoantibodies) approaching 20% [36,37]. Hypothyroidism is persistent in the majority of 
patients [33,38], even though although transient hypothyroidism has also been described 
[39]. The presence of anti-thyroperoxidase (anti-TPO) antibodies before treatment 
considerably increases the risk of hypothyroidism [40-42]. Thyroid abnormalities can occur 
as early as 4 weeks and as late as 23 months after initiating treatment, with a median of 4 
months [30,34].  
Interferon- has also been associated with classical Graves disease and sometimes Graves’ 
ophthalmopathy also develops, however the latter is less common [30]. This condition does 
not generally remit on withdrawal of the drug [35]. 
Several evidence supports the hypothesis that thyroid toxicity may likely be related to an 
autoimmune response to interferon-. Overexpression of MHC class I antigens are 
associated with activation of cytotoxic T-cells resulting in cellular destruction [43]. It has 
been reported that interferon- increases MHC class I expression on thyroid tissue from 
Graves patients, provided that lymphocytes are present in the thyroid tissue [44]. Hence, 
interferon- might worsen local immune response in subjects who have preexisting 
subclinical thyroiditis with intrathyroidal lymphocytes [44]. In addition, interferon- can 
shift the immune response to a Th1-mediated immune response, with increased 
production of the proinflammatory cytokines interferon-γ and interleukin-2, which may 
in turn amplify an autoimmune response. Interferon- has been demonstrated to elicit a 
direct damage on thyroid cells, which may be responsible for the onset of destructive 
thyroiditis [28,35,42,45]. However, despite accumulating evidence, the precise 
mechanisms underlying thyroid toxicity associated to interferon, especially in cancer 
patients, remain to be elucidated. 
Levothyroxine (LT4) therapy is indicated as treatment of interferon-induced 
hypothyroidism and withdrawal of interferon is not generally needed. When destructive 
thyroiditis is present, treatment with corticosteroids is needed and β-blockers are often 
useful to control the signs and symptoms of thyrotoxicosis. When interferon causes 
hyperthyroidism, antithyroid agents such as methimazole or propylthiouracil may be 
administered, if clinically indicated. In patients with relapsing flares of thyroiditis during 
prolonged courses of interferon-, ablation with 131I during remission may be offered to 
prevent further episodes of the condition [46]. 
Despite specific recommendations for patients treated with interferon- for oncological 
diseases are lacking, it appears rational to apply the recommendations available for patients 
with hepatitis C [47]. In particular, the same serological screening is suggested, including 
pretreatment TSH and anti-TPO antibodies evaluation, followed by TSH serum 
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measurement every 2 months and then every six months in the case of negative anti-thyroid 
peroxidase (anti-TPO) antibodies [1]. 
3.1.2. Interleukin-2 
Interleukin-2 is a cytokine involved in several mechanisms of immune response, including 
activation of natural killer cells and antigen-specific T-cells. These properties are used to 
stimulate tumor cell killing, also in combination with interferon or lymphokine-activated 
killer cells. Interleukin-2 is approved for the treatment of metastatic melanoma and RCC, 
although its use has been recently reduced in concomitance with the availability of more 
effective and better tolerated agents. 
Several autoimmune side-effects have been associated to interleukin-2 therapy, including 
thyroid disease with an incidence of 10%–50% [48-54]. Hypothyroidism usually occurs 4–17 
weeks after initiation of treatment [48,49]. It may be reversible following discontinuation of 
the drug [49,55]. Most patients who developed hypothyroidism showed positive anti-TG or 
anti-TPO antibodies. In addition to hypothyroidism, thyroiditis and thyrotoxicosis have also 
been reported at a lesser frequency [55,56]. An early phase of presumably destructive 
thyrotoxicosis is common, with variable degrees of hyperthyroidism [57]. 
Evidence suggests that thyroid disease associated to interleukin-2 may be induced by 
stimulating autoreactive lymphocytes, leading to autoimmune thyroiditis. Patients under 
treatment with interleukin-2 showed high levels of interferon-γ and tumor necrosis 
factor-, which may trigger autoimmunity by enhancing the presentation of human 
leukocyte antigen class II and associated autoantigens by thyrocytes. Also, interleukin-2 
may have direct effects on thyrocyte functioning [58,59]. Increase in serum thyroid 
autoantibodies levels [48,53] and lymphocyte infiltration of the thyroid gland [57] were 
found in patients treated with interleukin-2, suggesting a cell-mediated autoimmune 
mechanism. Similarly to interferon, preexisting positivity of thyroid autoantibodies 
seems to predict an increased risk of developing hypothyroidism during interleukin-2 
treatment [49]. 
Occurrence of hypothyroidism was associated with a favorable response to treatment 
[48,60], but other studies did not confirm these results [61]. It has been suggested that 
thyroid dysfunction may develop more often in the responders because they receive longer 
courses of the treatment [46,62]. Patients with interleukin-2-induced hypothyroidism may be 
treated with LT4, while thyrotoxicosis only requires symptom control with β-blockers and 
corticosteroids. Measuring TSH before treatment and then every 2–3 months during 
treatment with interleukin-2 is advisable [1]. 
3.2. Thalidomide and lenalidomide 
Thalidomide and lenalidomide are immunomodulatory drugs with antineoplastic activity 
[63,64]. These agents enhance T-cell stimulation and proliferation, induce endogenous 
cytokine release, and increase number and function of natural killer cells, thus enhancing 
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immune-mediated destruction of tumor cells. They also inhibit proliferation and induce 
apoptosis of tumor cells and exert antiangiogenic activity [63,64].  
Thalidomide and lenalidomide are approved for the treatment of multiple myeloma. 
Lenalidomide has also been approved for 5q myelodysplastic syndrome. Both agents are 
under evaluation for the treatment of several solid tumors, including thyroid cancer [65-67] 
and for a range of autoimmune diseases [68]. 
Hypothyroidism has been associated to treatment with these drugs with varying grades and 
frequency [68-71]. In a recent study on patients affected by multiple myeloma and treated 
with thalidomide [69], subclinical hypothyroidism was reported in 20% of participants, and 
7% showed overt hypothyroidism, mostly occurring 1–6 months after initiating treatment 
[69]. 
Lenalidomide is more potent and showed a more favorable toxicity profile compared to 
thalidomide [72,73]. Hypothyroidism due to lenalidomide has been reported in 5%–10% of 
patients [74,75]. Thyroid abnormalities were found in 10 out of 170 patients who received 
lenalidomide for various hematological cancers. After a median of 5 months of therapy the 
patients reported both hypothyroidism and thyrotoxicosis. However, many of them had 
been exposed to prior radiation or thalidomide [76]. 
Many mechanisms have been suggested for the hypothyroidism induced by these drugs 
[69], including inhibition of thyroid hormone secretion [77] or a reduction of iodine uptake 
into follicular cells [78]. Most probably, since thalidomide and lenalidomide exert an 
antiangiogenic activity, compromise the blood flow to the thyroid may explain thyroid 
toxicity [69]. In some patients, TSH suppression has been documented before the 
development of hypothyroidism, suggesting ischemic thyroiditis [69]. Alternatively, a 
thyrotoxicosis triggered by an immune-mediated destructive thyroiditis may be 
hypothesized. This condition may be induced by deregulation of cytokine levels or through 
direct effects on T-lymphocytes [69]. A direct toxic effect on thyroid cells is also possible, but 
this has not been evaluated. TSH measurement before treatment and then every 2–3 months 
during treatment is recommended [1,79]. 
3.3. Anti-CTLA4 monoclonal antibodies 
Ipilimumab and tremelimumab are monoclonal antibodies directed against cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4) (anti–CTLA-4 mAbs), a receptor expressed on T-
cells that exerts a suppressive effect on the immune response after T-cell/antigen-presenting 
cell interaction [80]. Blocking the receptor, an increased T-cell activation and antitumor 
effects are obtained. Ipilimumab is approved for the treatment of unresectable or metastatic 
melanoma. 
These agents have been associated with several immune-related adverse events (IRAEs), 
most frequently enterocolitis, hepatitis, cutaneous reactions [81-83]. The spectrum of 
autoimmune endocrine adverse events experienced by patients treated with anti–CTLA-4 
mAbs includes hypopituitarism, primary thyroid disease, and sporadically primary adrenal 
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insufficiency [84]. The prevalence of autoimmune hypophysitis varies among different 
studies (0%–17%) [85], being 3-5% in larger studies. Similarly to classical autoimmune 
hypophysitis, secondary hypothyroidism has been reported in patients who develop 
hypophysitis induced by anti-CTLA-4 monoclonal antibodies. 
Direct damage to the thyroid induced by these agents presents two clinical common forms: 
hyperthyroidism in Graves’ disease and thyroid destruction with hypothyroidism in 
Hashimoto’s thyroiditis. Since these conditions are classically included in autoimmune thyroid 
diseases phenotype and previous studies suggested that CTLA-4 is a candidate gene conferring 
susceptibility to thyroid autoimmunity [86], an autoimmune pathogenesis has also been 
suggested for thyropathies induced by anti-CTLA4-mAbs (anti-CTLA4-IT). The incidence of 
these conditions varies from 0 to 4% among the different trials. In two studies [87,88], 
tremelimumab (15 mg/Kg body weight) was associated with thyreopathy (hyper-
/hypothyroidism, autoimmune-thyroiditis, or Graves’ disease) in 4% of cases. In studies on 
ipilimumab, the reported incidence of anti-CTLA4-IT was apparently lower, namely 0-2%, 
being mild hypothyroidism the most frequent thyroid side-effect. Recently, Hodi et al. in a large 
phase III trial, reported for the first time an improvement in overall survival obtained by 
ipilimumab in pretreated patients affected by metastatic melanoma [89]. The treatment was 
associated with thyroid disorders or abnormal thyroid function tests in approximately 2% of 
patients. In a randomized phase II study on a cohort of 115 patients affected by metastatic 
melanoma, evaluating the potential protective effect of budesonide on IRAEs induced by 
ipilimumab, hypothyroidism was diagnosed in 5.3% of patients who received ipilimumab with 
placebo (3 out of 57 patients; with severe hypothyroidism in one of them, 1.8%), compared with 
no cases in the group of patients treated with budesonide as well. These data suggest a potential 
protective effect of budesonide in terms of reduced incidence of ipilimimab-related thyroiditis, 
but this hypothesis needs to be confirmed in specifically designed clinical trials [90]. 
In a phase I study [91] evaluating the combination of ipilimumab (10 mg/Kg every 3 weeks 
for 4 cycles, than every 3 months) with bevacizumab (7.5 mg/kg - Cohort 1; 15 mg/kg - 
cohort 2 every 3 weeks) in a group of 21 patients affected by unresectable stage III or stage 
IV melanoma, thyroiditis was diagnosed in 4 (19%) patients. No cases of endocrine-IRAEs 
were reported in a trial on 36 patients who received both ipilimumab (0.1-3 mg/kg; 24 
patients received the higher dose) and interleukin-2 (720,000 IU/kg every 8 hours) which is 
not infrequently associated with autoimmune thyroiditis [92].  
The onset of anti-CTLA4-IT appears rather earlier than other IRAEs, occurring after 2-4 
infusions. In most cases the anti-CTLA4-ITs have a subclinical course or may be transient. 
Alternatively, this condition may be characterized either by hypothyroidism with increased 
serum TSH concentrations, normal free-T4, and presence of anti-TPO antibodies, less 
frequently anti-TG antibodies or evolve in permanent hypothyroidism, requiring thyroid 
hormone supplementation [93]. 
Sporadic cases of Graves’ ophthalmopathy associated with ipilimumab therapy in euthyroid 
patients have been reported [82,94]. In these cases the effective treatment was to administer 
a high dose of glucocorticoids in the acute phase, rapidly tapered down and continue with 
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hydrocortisone, if required. None of the patients affected by anti-CTLA4-IT showed 
concomitant hypophysitis or other IRAEs. 
Patients who need to receive anti–CTLA-4 mAbs should be carefully informed on the 
importance of observing and early reporting signs or symptoms potentially related to 
IRAEs, and that these symptoms may occur weeks to months after starting treatment. In 
these patients, TSH, free-T4, serum electrolytes, serum glucose, and blood cell counts should 
be assessed before initiating treatment and before each cycle. 
3.4. Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors (TKIs) have emerged as a new class of molecular targeted anti-
cancer agents with proven efficacy in several types of carcinoma and in some hematologic 
cancers. At the moment, about 150 kinase-targeted drugs are in clinical development and 
many more are in various stages of preclinical development [95]. 
The registered kinase inhibitors are small molecules, that, with sporadic exceptions, exert 
their pharmacological action at the ATP-site of a wide variety of tyrosine kinases critical for 
tumor cell survival and proliferation and angiogenesis. TKIs compete with ATP for binding 
to the catalytic domain that act by preventing ATP binding to these targets with different 
selectivity, potency and pharmacokinetic properties. However, despite their inherent 
selectivity, the available TKIs showed a variable grade of affinity for the different tyrosine 
kinases, but none specific for a single kinase. In addition, interference is frequently extended 
to off-target intracellular processes of normal cells. As a direct consequence, TKIs may cause 
a number of infrequent or even new toxicities. TKI-induced endocrine side effects mainly 
include thyroid dysfunction and disease, but also may be responsible for gonadal and 
adrenal dyfunction, bone and glucose altered metabolism, impairment in linear growth and 
fetal development [96]. 
Two types of thyroid dysfunctions have been observed with TKIs [97]. The first is 
worsening of hypothyroidism in patients under satisfactory treatment with thyroid 
hormone replacement. This effect was initially noted in patients under treatment with 
imatinib, but also other TKIs were found responsible for increase in LT4 supplementation in 
hypothyroid patients [98-102]. The second type of thyroid disturbance is primary 
hypothyroidism in patients with previously normal thyroid function. Almost all TKIs are 
responsible, at a variable extent, of primary hypothyroidism, with the exception of gefitinb 
and erlotinib. 
The mechanisms of TKI-induced thyroid dysfunction are unclear. An increase in the 
requirement of replacement therapy with LT4 during certain TKIs has been suggested to be 
dependent on possible interference of the drug at nondeiodination clearance of LT4 [98]. 
Several drugs (e.g. phenobarbital, phenytoin, carbamazepine, rifampicin, and nicardipine) 
can increase thyroid hormone clearance through the induction of hepatic microsomal 
enzymes, including mixed function oxygenases and uridine diphosphate–
glucuronosyltransferases [103]. These drugs can cause hypothyroidism in patients who 
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undergo LT4 [11,104-106]. For example, imatinib is a potent competitive inhibitor of several 
mixed function oxygenases (CYP2C9, CYP2D6, and CYP3A4/5), and the induction of uridine 
diphosphate–glucuronosyl transferases has been hypothesized to be a possible mechanism 
of interference of imatinib on levothyroxine metabolism [98]. Alternatively, an interference 
of sunitinib with thyroid hormone action at the pituitary level has been suggested [122]. 
TKI-induced hypothyroidism (de novo primary hypothyroidism) may have several 
explanations. In some cases thyrotoxicosis may precede the development of 
hypothyroidism, suggesting a thyroiditis-induced thyrotoxicosis [107,108,123]. Other 
possible mechanisms include direct toxic effects on thyrocytes, namely the reduced 
synthesis of thyroid hormones related to inhibition of thyroid peroxidase activity [109], 
impaired iodine uptake [110], the drug induced regression of the gland vascular bed with 
significant capillary alteration and reduction in density [111]. However, a role for iodine 
uptake in TKI-hypothyroidism was not confirmed by in vitro studies [112] and anti-
peroxidase effect seems unable to provide an explanation for cases with initial destructive 
thyrotoxicosis, or with thyroid atrophy. 
Induction of Hashimoto thyroiditis has also been proposed [113], although Hashimoto 
thyroiditis is unlikely to be the main mechanism because of the low prevalence of anti-TPO 
antibodies. 
The most likely explanation is that the thyroid dysfunction may be related to the effects of 
these agents on tyrosine kinase receptors involved in vascular function, such as vascular 
endothelial growth factor (VEGF) receptor (VEGFR). This could cause a reduction in thyroid 
blood flow to this extremely vascular gland. If the blood flow decreases rapidly, an ischemic 
thyroiditis could result, leading to a transient period of thyrotoxicosis. If the decreased 
blood flow develops more slowly, gradual thyroid destruction may occur with resulting 
hypothyroidism [114]. Supporting evidence for this theory include findings that thyroid 
cells express VEGF and VEGFR mRNA, and preclinical studies in mouse models have 
shown glandular capillary regression with TKI exposure [115]. In humans, case reports 
demonstrated reduced thyroid volume and reduced vascularity by Doppler ultrasound 
[116,117], with rapid increase in the size of the thyroid with cessation of sunitinib. This 
reduced thyroid volume secondary to reduced blood flow, may also explain the impaired 
radioactive iodine uptake in vivo, but not in vitro [118]. However, the role of VEGF in thyroid 
signaling is uncertain. Unlike treatment with antiangiogenic TKIs, bevacizumab is not 
associated with altered thyroid homeostasis [119]. In addition, in vitro experiments showed 
that VEGF reduces TSH induced iodine uptake by thyroid cells, and inhibition of VEGF 
restores iodine uptake [120]. Other factors, such as platelet derived growth factor α and c-
KIT, contribute to maintaining thyroid homeostasis, but so far no data on their role in this 
toxicity have been published. 
3.4.1. Imatinib  
Imatinib inhibits the kinase activity of the tyrosine kinases of breakpoint cluster region 
proto-oncogene ABL1 (BCR-ABL fusion protein), c-Kit and platelet derived growth factor 
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receptor (PDGFR) /β. It is currently approved for the treatment of chronic myeloid 
leukemia, gastrointestinal stromal tumors (GIST) and dermatofibrosarcoma protuberans. 
The influence of daily 400–800 mg imatinib on LT4 was reported in a cohort of 11 patients 
(10 with medullary thyroid carcinoma and 1 with GIST) [98]. Among the patients with 
medullary thyroid carcinoma, eight underwent thyroidectomy and received LT4 and three 
had thyroid carcinoma in situ. Thyroid function was evaluated before, during and 2 weeks 
after therapy with imatinib or LT4. Symptoms of hypothyroidism occurred in all patients 
who had undergone thyroidectomy, but not in those with intact thyroid. Patients who had 
undergone thyroidectomy had markedly elevated TSH levels, and required an increase of 
LT4 during imatinib dosing. The effect was reversible after discontinuation of treatment, 
suggesting that imatinib might be the causative agent. 
In another study on 68 patients with intact thyroid gland who received imatinib for chronic 
myeloid leukemia, no case of drug-induced alterations in thyroid laboratory parameters was 
observed. These data sustain the hypothesis that imatinib-induced thyroid dysfunction is 
limited to athyreotic patients and are not the consequence of a direct action of the drug on 
thyroid gland [121], but more probably of an interference of the drug in the nondeiodination 
clearance of LT4 through the induction of hepatic microsomal enzymes [98]. 
3.4.2. Sunitinib 
Sunitinib is an oral, multitarget inhibitor of VEGF receptor 1 (VEGFR1), VEGFR2, Fms-like 
tyrosine kinase 3 (Flt3), colony stimulating factor 1 receptor (CSF1R), RET, c-Kit, and 
PDGFR. This agent has been found to influence the thyroid function of patients with GIST 
or RCC.  
In total, 2 out of 56 patients with RCC and a history of well controlled hypothyroidism, and 
7 out of 21 patients with imatinib-resistant GIST, had a worsening hypothyroidism during 
sunitinib treatment [109,111,122], reported the case of a woman with GIST who was resistant 
to imatinib and received LT4 after thyroidectomy and 131I-ablation for follicular thyroid 
carcinoma. The patient’s dose of LT4 needed to be increased after sunitinib treatment. In this 
report, the marked increase in TSH levels has been attributed to a potential interference of 
sunitinib with thyroid hormone action at the pituitary level [122]. 
Desai et al. [123] prospectively evaluated the thyroid function tests (TFTs) in a phase I/II 
study of sunitinib therapy in 42 patients with imatinib-resistant GIST. Most patients 
received 50 mg sunitinib daily every 4–6 weeks, each consisting of 2–4 weeks of sunitinib 
followed by 2 weeks of wash-out. Initially, TFT were performed only if clinically indicated. 
Thereafter, serum TSH was evaluated before each sunitinib cycle. In total, 42 patients with 
normal baseline TFT who received at least 3 sunitinib treatment cycles for a median of 37 
weeks were evaluated. Abnormal serum TSH concentrations were documented in 26 
patients (62%). Sunitinib caused persistent primary hypothyroidism in 15 patients (36%), 
after an average of 50 weeks of therapy (range 12–94 weeks). Seven additional patients 
(17%) experienced transient, mild serum TSH elevation (5.0–7.0 mU/L). In 4 patients TSH 
was suppressed, but they discontinued treatment before the TFTs could be repeated. Out of 
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15 patients with hypothyroidism, 6 (40%) had at least one TSH value below 0.5 mU/L before 
developing the condition, which suggests a thyroiditis-induced thyrotoxicosis. The risk of 
hypothyroidism increased with the duration of sunitinib therapy. Subclinical or overt 
hypothyroidism was observed in 4 out of 22 patients [18%] who received sunitinib for 9 
months, and in 5 of 17 patients (29%) who received sunitinib for longer than 12 months. In 
patients treated for longer than 96 weeks, 90% developed increased levels of TSH. The mean 
time to onset of hypothyroidism was 50 weeks. Among the patients with TSH 
concentrations greater than 10 mU/L, none had spontaneous biochemical resolution. During 
the titration of LT4, serum TSH values remained elevated for a median of 17 weeks (range 
4–117 weeks). The TSH concentrations returned to normal in all patients who received 
conventional doses of LT4. Interestingly, in 2 patients with hypothyroidism and normal 
baseline TFTs, ultrasonography revealed atrophic thyroid tissue, which suggests destructive 
thyroiditis. This clinical trial was the first to report the prevalence of sunitinib related 
hypothyroidism [123]. 
Rini et al. [111] described thyroid abnormalities in a retrospective study of 66 patients with 
metastatic RCC treated with sunitinib. In all, 30 patients were pretreated with cytokine-
based therapy (6 of them were treated with bevacizumab), and 30 patients were treatment-
naive. All patients received the standard sunitinib dose of 50 mg daily for 4 weeks, followed 
by 2 weeks off therapy. TFT assessment, including free thyroxine index, was initiated in 29 
patients (and subsequently in another 37 patients) as a routine laboratory assessment at 
baseline and on day 28 of every even numbered cycle. Out of the 66 patients, 56 (85%) had 
one or more TFT abnormality. These abnormalities were consistent with hypothyroidism in 
all patients and primarily included the elevation of TSH, decreased levels of T3 and, less 
commonly, decreases in T4 and/or of the free thyroxine index. TFT abnormalities were 
detected early (the median time of detection was at cycle 2). Among patients with abnormal 
TFTs, signs and symptoms related to hypothyroidism were found in 47 patients (84%). 
These symptoms included fatigue, cold intolerance, anorexia, periorbital edema, fluid 
retention, and alterations in skin or hair. LT4 therapy was given at the discretion of the 
physician, on the basis of the degree of biochemical abnormality and/or clinical symptoms. 
A resolution of biochemical abnormalities occurred in all 17 patients treated with LT4, and 
an improvement of symptoms was recorded in 9 patients. Anti-TG antibodies were 
measured in 44 patients and were abnormal in 13 (30%). No association was observed 
between the presence of anti-TG antibodies and the incidence or severity of TFT 
abnormalities [111]. 
Feldman et al. [124] reported that hypothyroidism was found in 14 (18%) out of the 80 
patients enrolled in a prospective clinical trial that investigated the efficacy of sunitinib in 
metastatic RCC. Serum TSH levels were obtained only from symptomatic patients and 
ranged from 6.0 to 146.4 mU/L (normal range 0.35–5.5 mU/L). Hypothyroidism was detected 
after a median time of 10 months of therapy (range 1–26 months), being fatigue the 
predominant symptom. The Authors highlighted that the lower incidence of 
hypothyroidism reported might depend on the fact that TFT assessment was performed on 
symptomatic patients only [124]. 
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Wong et al. [109] explored the potential effects of sunitinib on thyroid function in a cohort of 
40 patients affected by different tumor histotypes, the majority of whom were affected by 
imatinib-resistant GIST. In this study a new onset or worsening condition of 
hypothyroidism occurred in 21 out of 40 patients (53%) patients who underwent TFTs. 
Patients developed elevated TSH levels after a median of 5 months of treatment (range, 1–36 
months). The median TSH level was 21.4 mU/L (range, 4.6–174 mU/L). The influence of 
sunitinib on peroxidase activity was assessed by testing its effects on guaiacol oxidation and 
protein iodination caused by lactoperoxidase. The potency of sunitinib antiperoxidase 
activity was about 25% of that noted with propylthiouracil. The Authors proposed that the 
antithyroid effect of sunitinib is mediated by the inhibition of peroxidase activity, which is 
involved in the synthesis of the thyroid hormone [109]. 
Wolter et al. [125] prospectively evaluated the incidence of hypothyroidism in patients with 
GIST or metastatic RCC treated with sunitinib at the standard dose [125]. TFTs included 
assessment of serum TSH, T3, free thyroxine index and thyroid antibodies (anti-TG, anti-
TPO antibodies, and TSH receptor antibodies) and was measured on days 1 and 28 of each 
treatment cycle. The analysis revealed that 16 patients (27%) developed sub- or clinical 
hypothyroidism requiring thyroid hormone replacement and 20 patients (34%) showed at 
least one thyroid test abnormality. The median time to develop thyroid dysfunction was 4 
weeks and patients who did not develop hypothyroidism within the first cycles did not 
develop hypothyroidism later during therapy. 
In another prospective phase I-II study, Mannavola et al. [110] evaluated TFT (serum TSH, 
free T3 and T4, thyroglobulin, anti-TG and anti-TPO antibodies) in 24 patients with GIST 
who were treated with sunitinib (4 weeks of 50 mg daily and 2 weeks of withdrawal). 
Urinary iodine was measured in 18 patients and urinary fluorine was assessed in 10 
patients. Thyroid ultrasonography and echocolor-Doppler were performed, both at 
enrollment and after a variable number of treatment cycles. To study thyroid function, 123I 
thyroidal uptake and scintigraphy were performed in 6 unselected patients at the end of the 
treatment and withdrawal periods. Hypothyroidism was documented in 46% of patients, 
and a transient elevation of TSH levels in 25% of cases. The overall prevalence of elevated 
TSH levels after sunitinib was 71%. At onset, hypothyroidism was subclinical in all but one 
patient with Hashimoto thyroiditis, the only one with detectable antithyroid autoantibodies. 
TSH levels were found to fluctuate according to whether treatment was given or 
withdrawn, and progressively increased during treatment. In most cases, progressive 
worsening of hypothyroidism was shown, but in a few cases a sudden development of 
severe hypothyroidism was observed. The normal echographic and echocolor-Doppler 
patterns, obtained both at baseline and during treatment, indicate that hypothyroidism is 
unlikely to be the consequence of a direct toxic effect on thyroid cells or secondary to an 
autoimmune process. Inhibition of iodine uptake seems to be a more likely explanation for 
hypothyroidism. Indeed, radioiodine uptake impairment has been demonstrated by a 
reduced uptake at the end of treatment periods, with a partial or total recovery during the 
withdrawal phase. Of particular interest was the observation of a blunted early 123I uptake 
curve, which suggests an alteration in the uptake phase rather than in the organification 
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process. The Authors noted that after sunitinib withdrawal, TSH levels returned to the 
normal range in a maximum of 60 days. 
Interestingly, the association between TKI-induced thyroid dysfunction and clinical 
efficacy has been demonstrated in two larger studies. Schmidinger et al. [126] in a 
prospective analysis of 87 patients with metastatic RCC who were to receive treatment 
with sunitinib or sorafenib, thyroid function was monitored every 4 weeks during the first 
2 months of treatment and every 2 to 4 weeks thereafter. Subclinical hypothyroidism was 
present in five patients at baseline and was diagnosed in 30 patients (36.1%) within the 
first 2 months of therapy. Patients with subclinical hypothyroidism had a statistically 
significant objective remission rate of 28.3% versus 3.3% in euthyroid patients (p<0.001) 
and median duration of survival (not reached versus 13.9 months in euthyroid patients; 
p=0.016). In addition, in a multivariate analysis, the development of subclinical 
hypothyroidism within 2 months of treatment was found to be an independent predictor 
of survival (p=0.014). In another study on patients with metastatic RCC who received 
sunitinib or sorafenib, Riesenbeck et al. [127] found that 21 (38.1%) out of the 66 evaluable 
patients developed hypothyroidism. Hypothyroidism was associated with a longer PFS 
(16.0 ± 0.8 months versus 6.0 ± 0.8 months, p=0.032). In agreement with the study by 
Schmidinger et al. [126], hypothyroidism was found to be an independent predictor of 
survival (p=0.01) in a multivariate analysis. 
3.4.3. Sorafenib 
Sorafenib is an oral multikinase inhibitor that inhibits the kinase activity of RAF/MEK/ERK, 
VEGFR2 and VEGFR3, Flt3, fibroblast growth factor receptor 1, RET, cMET, PDGFR β, Kit 
and other receptors involved in tumor progression and angiogenesis. It is approved for the 
treatment of advanced RCC and unresectable hepatocellular carcinoma. In addition, it is 
under clinical evaluation in a number of tumor types, including lung, pancreatic, prostate, 
melanoma and differentiated thyroid cancer. Tamaskar et al. [114] retrospectively 
investigated the incidence of TFT abnormalities in 39 patients with metastatic RCC treated 
with 400 mg sorafenib twice daily. Most patients had received at least one prior treatment. 
Out of the 39 patients, 16 (41%) had one or more serum TFT values outside the laboratory 
normal reference range during treatment with sorafenib. The median timing of the 
abnormal test was 1.8 months (range 0.6–7.3 months). Biochemical hypothyroidism occurred 
in 7 out of 39 patients (18%) during treatment, which was first observed 2–4 months after 
sorafenib initiation. Six of these patients had mild TSH level elevations (5.5–10.0 mU/L). 
Another patient showed a rapid onset of hypothyroidism with TSH level rising from 5.74 to 
160.64 mU/L, and T3 level decreasing from 72 to 49 ng/dl over 1.5 months. One patient had 
normal TSH concentration (2.42 mU/L) but low T3 and T4 at 4 months after starting 
sorafenib treatment, these abnormalities worsened over the next 4 months with further 
reductions of T3 and T4 levels, and abnormal TSH (9.930 mU/L). Both these patients 
received LT4. In two of the seven hypothyroid patients anti-TG antibody titers increased; 
two patients had persistent serum TSH elevation and in one case a normalization of the TSH 
values was observed. 
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Clement et al. [128] prospectively monitored thyroid function in 38 patients with metastatic 
RCC who were treated with sorafenib 400 mg twice daily. Thyroid function was assessed at 
baseline and on day 1 of each treatment cycle. Out of 23 patients with normal baseline 
thyroid function, seven patients (30%) developed at least one elevated serum TSH and 1 
patient (5%) developed low TSH levels. For these abnormalities no therapy was required. In 
addition, out of 15 patients with either thyroid dysfunction at baseline or previous treatment 
potentially interfering with thyroid function, two patients with baseline subclinical 
hypothyroidism (defined as an increase in serum TSH above normal and ≤ 10 mU/L, with 
normal T3 and T4 values) developed clinical hypothyroidism (TSH ≥ 10 mU/L or T3 and T4 
values below the normal range) requiring thyroid hormone replacement therapy. 
In another prospective observational study [129] on 69 Japanese patients affected by metastatic 
RCC refractory to cytokine therapy and subsequently treated with sorafenib for at least 12 
weeks, thyroid function was assessed before and every 4 weeks after the initiation of sorafenib 
treatment. Forty-six (67.7%) patients developed hypothyroidism. Interestingly, 11 (23.9%) of 
these patients first showed a suppressed TSH value accompanying the increase in free T3 
and/or free T4, before developing hypothyroidism. This pattern clearly suggests that sorafenib 
may have induced thyroiditis. LT4 was needed by 4 patients (5.8%) who presented severe 
clinical symptoms caused by hypothyroidism. Among several factors examined, only age was 
significantly associated with the risk of developing hypothyroidism.  
Sorafenib-associated thyroid dysfunction was not reported in two registration trials in 
patients affected by advanced hepatocellular carcinoma (HCC). More recently, in a series of 
38 consecutive patients with HCC treated with sorafenib, 5 (13%) of them developed 
subclinical hypothyroidism (TSH levels, 7,41 μIU/mL; range, 6,38-8,94 μIU/mL (unpublished 
data) [130]. Other case reports of patients affected by HCC showed progressive destructive 
thyroiditis after taking sorafenib. These data highlight the possibility that also 
hypothyroidism induced by sorafenib may be the result of an initial thyrotoxicosis [131]. 
Abdulrahman et al. [132] in a small prospective study on 21 patients with progressive 
nonmedullary thyroid carcinoma treated with sorafenib, measured serum total T4, free T4, 
total T3, free T3, reverse T3, and TSH concentrations at baseline and after 26 weeks of 
treatment with sorafenib. Results from this study suggested that sorafenib enhances T4 and 
T3 metabolism, which may be probably caused by an increased type 3 deiodination. 
3.4.4. Motesanib 
Motesanib diphosphate is a highly selective, oral inhibitor of VEGFR-1, -2, and -3; PDGFRs 
and c-KIT. The association between motesanib and thyroid function was recognized in a 
phase II study of 93 patients with progressive radioiodine-resistant differentiated thyroid 
cancer who daily received motesanib diphosphate [102]. All the patients had previously 
undergone thyroidectomies and were on thyroid hormone replacement therapy. Increased 
serum TSH concentrations, hypothyroidism or both were observed in 20 patients (22%). The 
Authors suggested that alterations in the absorption or metabolism of LT4 may explain 
changes in thyroid hormone levels while on motesanib. 
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In a phase II study [101] on 91 patients affected by locally advanced or metastatic medullary 
thyroid cancer (MTC), motesanib was taken orally at the standard dose for up to 48 weeks 
or until unacceptable toxicity or disease progression. Thirty-seven patients (41%) had 
elevated serum TSH levels compared with baseline and/or hypothyroidism.  
In another phase II study assessing the tolerability and activity of motesanib in 138 patients 
with imatinib-resistant GIST, only 3 patients (2%) developed hypothyroidism, but only in 
one case related to treatment [133]. 
3.4.5. Vandetanib 
Vandetanib is an oral inhibitor of VEGFR-2 and -3, RET kinases, and at higher 
concentrations, the epidermal growth factor receptor kinases. This drug has been approved 
in the United States for unresectable locally advanced or metastatic MTC and is under 
evaluation in phase III trials on patients affected by several cancer types [134]. 
In a phase II study of vandetanib, 19 patients with advanced hereditary MTC received 
vandetanib 100 mg daily [135]. All patients had undergone prior total thyroidectomy and 
were receiving LT4 therapy. In all 17 patients who had available baseline TFTs, an 
increase in serum TSH levels was observed. TSH elevation reached a maximum by day 84 
after the start of vandetanib treatment with a median 7.3-fold increases over baseline. No 
patients were reported to have symptomatic hypothyroidism, but LT4 was increased in 
two patients. 
Interestingly, in a study on 39 patients with progressive medullary or differentiated thyroid 
cancer included in two randomized placebo-controlled trials using vandetanib 300 mg/day 
[136] LT4 had to be increased by 50 μg/d to maintain serum TSH within the normal range, 
probably by increased type 3 deiodinase activity as described using sorafenib [132]. 
3.4.6. Axitinib 
Axitinib is an oral TKI that acts selectively inhibiting all VEGFR kinases [137]. The drug is 
approved by the FDA for the treatment of advanced RCC after the failure of one prior 
systemic therapy. In a Japanese study on 18 patients affected by various solid tumors 
receiving axitinib at different dosage, 16 (89%) patients experienced elevation in serum TSH 
above the upper limit of normal range [138]. 
In a phase II study on 60 patients with thyroid cancers resistant or not appropriate for 131I, 
who received axitinib (starting dose, 5 mg orally twice daily), no thyroid tests abnormalities 
were registered, except for the initial decreases in thyroglobulin seen in most patients, 
regardless of their clinical response to therapy. In another phase II study on 62 patients with 
metastatic RCC refractory to prior therapies, including sorafenib, G1-2 hypothyroidism was 
registered in 29% of patients [139]. In preclinical studies with axitinib inhibition of VEGFR-2 
and VEGFR-3 induced by axitinib lead to thyroid capillary regression [115,140]. Again, 
destructive thyroiditis mediated by the destruction of thyroid capillary appears a plausible 
mechanism of action explaining axitinib-associated hypothyroidism. 
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3.4.7. Nilotinib 
Nilotinib is a second-generation TKI with greater potency and specificity for BCR-ABL 
inhibition compared with imatinib [141,142]. It is approved for the treatment of 
Philadelphia-positive chronic myeloid leukemia (Ph-positive CML). Kim et al. [143] 
retrospectively assessed the effect of nilotinib on TFT in 55 patients with Ph-positive CML. 
In 12 patients (22%), TFTs were consistent with hypothyroidism (6 subclinical, 6 clinical) 
and in 18 (33%) patients with hyperthyroidism (10 subclinical, 8 clinical) at some point 
during their therapy. Six (11%) of these patients were on thyroid medication prior to starting 
the nilotinib and in most patients an increase in LT4 dose was not required. In 4 patients 
evidence of thyroiditis was found (3 had positive anti-thyroid antibodies) with an episode of 
hyperthyroidism preceding the development of hypothyroidism. 
Recently, a case of overt hypothyroidism following initiation of treatment with nilotinib has 
been described in a 76-year-old euthyroid male with CML [144]. Serum TSH was 30.23 
μU/mL with low free T4 and free T3, and negative anti-thyroid antibodies. The ultrasound 
examination showed a normal size gland, markedly decreased inhomogeneous echo signals 
and slightly reduced vascularity, all compatible with thyroiditis. In this case symptoms 
dramatically regressed following the initiation of LT4 and nilotinib was not withdrawn. 
3.4.8. Dasatinib 
Dasatinib is another second-generation TKI with activity against BCR-ABL and Src family 
kinases that is approved for the treatment of imatinib-resistant Ph-positive CML and Ph-
positive acute lymphoblastic leukemia [145]. In a retrospective survey on patients with Ph-
positive CML who received dasatinib, 5 (50%) patients had TFT abnormalities consistent 
with hypothyroidism (4 subclinical, 1 clinical) and 2 patients (20%) had thyroid values 
consistent with subclinical hyperthyroidism. No patient required LT4, except one patient 
who developed hypothyroidism and was also taking amiodarone, a medication known to 
cause thyroid dysfunction. Two patients were on LT4 prior to starting dasatinib and 
modification of LT4 was not required [143]. 
3.4.9. Pazopanib 
Pazopanib is an oral angiogenesis inhibitor targeting VEGFR-1, PDGFR, and c-Kit. 
Pazopanib is under clinical development for the treatment of multiple tumor types and has 
been recently approved for the treatment of advanced RCC. Preliminary data on the 
incidence and severity of thyroid dysfunction in patients who received pazopanib as 
treatment for RCC in 3 prospective trials have been recently reported [146]. TFTs were 
systematically assessed in 578 patients with serum TSH values collected at baseline and 
every 12 weeks and serum free T3 and T4 at baseline and if TSH was abnormal during the 
treatment. Elevated TSH (>5 μUI/mL) before initiating pazopanib was found in 37 (6%) 
patients. TSH value >5 μUI/mL during the treatment was found in 167 (29%) patients. Overt 
hypothyroidism was diagnosed in 34 (6%) patients. Hyperthyroidism was seen in 8 (1%) 
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patients. Only 20 (3%) patients with a TSH elevation received LT4. Hypothyroidism was 
registered as a Grade 1/2 adverse event in 26 (4%) patients. Thyroid dysfunction was never 
reported as a severe adverse event in any patient. 
3.4.10. Cediranib 
Hypothyroidism was also reported with cediranib, another blocker of VEGFR 1-3 and c-Kit 
kinases in 45% of patients affected by advanced non-small-cell lung cancer enrolled in a 
randomized, double-blind trial of carboplatin and paclitaxel taking either oral cediranib or 
placebo daily [147]. Similarly, in a randomized phase II study on 46 patients affected by 
recurrent epithelial ovarian or fallopian tube cancer and treated with cediranib as single 
agent, Grade 2 hypothyroidism occurred in 56% of patients [148]. Details regarding the rate 
of patients requiring LT4 or effects of this treatment on hypothyroidism-related symptoms 
was not reported.  
3.5. Bexarotene 
Bexarotene is a selective agonist of the retinoid X receptor (RXR), a nuclear hormone 
receptor. It is approved for the treatment of cutaneous T cell lymphoma and has been found 
to induce secondary hypothyroidism [102]. Bexarotene appears to interfere with the normal 
feedback of thyroid hormone on the pituitary gland [102,149]. T3 binding to its receptor in 
the pituitary leads to heterodimerization of the receptor with RXR, which suppresses 
transcription of the β-subunit of TSH, which is required for thyroid stimulation. Bexarotene 
also has TSH-independent effects on thyroid hormone metabolism. Thyroidectomized 
thyroid cancer patients receiving thyroid hormone replacement who started bexarotene had 
a dramatic decrease in total T3 and T4, and free T4 levels with TSH levels that failed to rise 
appropriately [150].This may be probably due to an effect on peripheral thyroid hormone 
metabolism via non-deiodinase mechanisms. 
4. Why is it important to assess thyroid function in cancer patients? 
Abnormalities of thyroid function induced by anticancer drugs are variably common, 
accordingly to the agent used. Identifying thyroid dysfunction and disease in cancer 
patients may have important consequences for diagnostic, therapeutic and prognostic 
purpose.  
Diagnostic challenges are tendered by symptoms of thyroid dysfunction. For example, 
fatigue and constipation are present in the majority of patients with hypothyroidism, but 
they may be caused also by underlying malignancy, antineoplastic treatment(s) received, or 
medications used for control of other symptoms (i.e. nausea or pain) [1]. Similarly, many 
symptoms of thyrotoxicosis are similar to those attributable to other complications, such as 
sepsis. Inability to diagnose the presence of thyroid dysfunction or disease as treatment-
related toxic effects may lead to misguided treatment strategies, unjustified dose reduction 
or even to treatment withdrawal [1]. In addition, unrecognized hypothyroidism or 
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thyrotoxicosis may affect the metabolism of other medications [151]. Finally, it should be 
considered that thyroid dysfunction, although rarely, can lead to life-threatening 
consequences in cancer patients, as warned by case reports of patients who experienced 
myxedematous coma [152] or impaired cardiac function [153,154] as a complication of TKI-
induced hypothyroidism (i.e. sunitinib). 
Therefore, clinicians should maintain an adequate level of surveillance for thyroid 
abnormalities when patients receive certain anticancer treatments, such as TKI or certain 
immunomodulatory drugs, present with symptoms consistent with hypothyroidism (i.e. 
constipation, bradycardia, hypothermia, unexpected weight gain, dry skin or dry hair and 
brittle nails) or thyrotoxicosis (i.e. palpitations, weight loss, heat intolerance, frequent bowel 
movements, tremor, proximal muscle weakness, tachycardia, lid retraction or lid lag, 
insomnia, irritability, fever). Of note, hypophysitis has recently emerged as an unusual, 
peculiar side effect of ipilimumab/tremelimumab. Symptoms like headache, visual 
impairment, nausea, vomiting, loss of appetite, fatigue, weakness, asthenia, fever, lethargy, 
hypotension, hypoglycemia and hyponatremia in patients recently treated with ipilimumab 
should lead physicians to suspect hypophysitis. The early diagnosis of this side-effect allows 
to prevent primarily a life-threatening complication such as adrenal insufficiency, but also 
central hypothyroidism and other endocrine consequences of hypopituitarism [84]. 
Monitoring thyroid function even in asymptomatic patients has emerged as a prognostic 
tool as well. A lower cancer risk and a more indolent disease has been noted in patients with 
primary hypothyroidism and breast cancer [155]. The association between the appearance of 
treatment-induced hypothyroidism has been related to an increased likelihood of response 
to therapy and even of better outcomes. The development of hypothyroidism following 
radiotherapy for head and neck cancer was associated with better survival [156]. 
Propylthiouracil-induced hypothyroidism was associated with improved survival in 
patients with glioma [157]. Thyroid autoimmunity may predict an improved tumor 
response to interleukin 2 therapy for melanoma [62] and RCC [48,49,60]. When patients with 
RCC are treated with sorafenib or sunitinib, a higher rate of remission and better overall 
survival are seen in those who developed hypothyroidism compared to those who did not 
[126,158]. Studies of anti-CTLA4 monoclonal antibodies suggest that the presence of 
immune-related adverse events, including hypophysitis and thyroiditis, is associated with 
better clinical outcomes [159]. 
In patients who are going to start drugs potentially associated with thyroid side-effects, an 
accurate screening for thyroid function should be carried out at baseline and monitored 
throughout the period of treatment and follow-up. Despite specific guidelines generated by 
high level evidence are lacking, rational approaches have been proposed [1,160]. 
Successful treatment of thyroid dysfunction such as hypo- and hyperthyroidism, is likely to 
improve patient quality of life and may prevent erroneous withdrawal from effective 
anticancer therapies. Patients with TSH greater than 10 mIU/L or with low free T4 levels, 
should receive thyroid hormone replacement with LT4 at an average dose of 1.6 μg/kg per 
day. In the case of coronary artery disease, a lower initial dose (e.g. 50 μg/d) should be used 
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for the first few weeks [1]. Monitoring thyroid hormone replacement is usually carried out 
by serum TSH measurements, aimed at maintaining TSH within the normal range. On the 
contrary, in patients who develop central hypothyroidism (i.e. secondary to bexarotene and 
anti-CTLA4 monoclonal antibodies), TSH concentrations cannot be used, and free T4 levels 
should be monitored, with a goal of about 1–1.5 ng/dL [1]. 
The treatment of subclinical hypothyroidism (TSH 5–10 mIU/L with a normal free T4) is 
questionable in cancer patients. In general, treatment of this condition is discouraged in a 
healthy population because there is insufficient evidence of benefit [161,162]. However, it 
may be offered to patients with subclinical hypothyroidism and antiTPO/anti-TG 
antibodies, hypercolesterolemia, thyroid nodules, or symptoms (i.e. fatigue) that may 
greatly worsen quality of life of patients [5]. In one study [111], at least half of patients who 
started LT4 for sunitinib-associated hypothyroidism had improvement of their symptoms of 
fatigue [111]. Conversely, Garfield et al. [163] warned that some preclinical, epidemiological 
and clinical evidence suggests that LT4 is permissive for tumor growth. Possible actions of 
thyroid hormones on cancer cells include the amplification of EGFR, phosphorylation of 
insulin-like growth factor 1 receptor, stimulation of migration, a direct trophic effect on 
tumor cells, cell specific anti apoptotic activity and angiogenesis [164]. 
Practical suggestions for the treatment of individual cancer patients showing TKI-induced 
subclinical hypothyroidism are available [5]. However, the best approach seems to to start 
low-dose LT4 in individual patients as a therapeutic trial [1]. This prudent method may be 
extended to patients who develop this condition as a side effect of other anticancer agents. 
However, specific prospective studies evaluating the influence of thyroid replacement 
therapy in cancer patients, not only in term of quality of life, but also in term of survival, are 
urgently needed [165]. Thyrotoxicosis induced by anticancer drugs may result from an 
Hashi-toxocosis or Graves’ disease. Thyrotoxicosis from thyroiditis is generally self-limiting 
and specific treatment is not required. Corticosteroid and β-blockers, usually propranolol, 
can be efficacious in symptom control. However, patients with this side effect should be 
monitored for subsequent hypothyroidism. Patients presenting with Graves disease, are 
usually treated with antithyroid drugs (i.e. methimazole), followed by 131I ablation if 
indicated. However, due to its complexity, anticancer drug-induced thyrotoxicosis is 
advisable to be managed under close consultation with an endocrinologist [1].  
5. Conclusions 
Thyroid dysfunctions are emerging as a variably common endocrine toxicity of several 
highly selective anticancer drugs. Routine testing for thyroid abnormalities in patients 
receiving these agents are recommended at baseline, during the treatment and follow up. 
Furthermore, thyroid function tests should be included in routine toxicity assessment of 
TKIs and possibly in other classes of targeted drugs under clinical evaluation. 
Hypothyroidism per se is not an indication for dose reduction or discontinuation of these 
agents. The clinical relevance of overt and subclinical hypothyroidism, the value of thyroid 
hormone replacement in individuals with abnormal serum TSH levels following anticancer 
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systemic therapy, and the correct timing of thyroid replacement therapy need to be more 
accurately defined. Additional prospective clinical trials are necessary to investigate these 
important aspects. In parallel, these trials could offer the unique opportunity to clarify the 
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